WuXi Biologics Enhances Manufacturing with New Single-Use Bioreactors

WuXi Biologics has bolstered its manufacturing capacity by installing three 5,000-liter single-use bioreactors. These bioreactors, now operational at their drug substance manufacturing facility, are expected to significantly enhance the company’s GMP production capabilities. The implementation of single-use technology is key to increasing flexibility, reducing contamination risks, and ensuring quicker batch turnovers. This expansion underscores WuXi Biologics' dedication to meeting the growing global demand for biologics and providing high-quality manufacturing services to their clients.

For more details, view the official press release.